These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 32534034)

  • 1. Incretin-based therapies and renin-angiotensin system: Looking for new therapeutic potentials in the diabetic milieu.
    Yaribeygi H; Maleki M; Sathyapalan T; Jamialahmadi T; Sahebkar A
    Life Sci; 2020 Sep; 256():117916. PubMed ID: 32534034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antioxidative Potentials of Incretin-Based Medications: A Review of Molecular Mechanisms.
    Yaribeygi H; Maleki M; Sathyapalan T; Jamialahmadi T; Sahebkar A
    Oxid Med Cell Longev; 2021; 2021():9959320. PubMed ID: 34007411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The journey to understanding incretin systems: Theory, practice and more theory.
    Yabe D; Kuwata H; Seino Y
    J Diabetes Investig; 2019 Sep; 10(5):1171-1173. PubMed ID: 31361402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.
    Zou H; Zhou B; Xu G
    Cardiovasc Diabetol; 2017 May; 16(1):65. PubMed ID: 28511711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.
    van Genugten RE; Möller-Goede DL; van Raalte DH; Diamant M
    Diabetes Obes Metab; 2013 Jul; 15(7):593-606. PubMed ID: 23216746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of incretin-based therapies in the management of type 2 diabetes.
    Bandyopadhyay P
    Drug News Perspect; 2009 Nov; 22(9):559-67. PubMed ID: 20072733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incretin-based therapies: facing the realities of benefits versus side effects.
    Lebovitz HE
    Diabetes Technol Ther; 2013 Nov; 15(11):909-13. PubMed ID: 24111860
    [No Abstract]   [Full Text] [Related]  

  • 8. [Cardiovascular Effects of Incretin-Based Therapies and Their Therapeutic Potential].
    Tyurenkov IN; Bakulin DA; Kurkin DV; Volotova EV
    Vestn Ross Akad Med Nauk; 2017; 72(1):66-75. PubMed ID: 29308856
    [No Abstract]   [Full Text] [Related]  

  • 9. Incretin pharmacology: a review of the incretin effect and current incretin-based therapies.
    Neumiller JJ
    Cardiovasc Hematol Agents Med Chem; 2012 Dec; 10(4):276-88. PubMed ID: 22827291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
    Jellinger PS
    Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updates of incretin-related drugs for the treatment of type 2 diabetes.
    Araki H; Matsumura T; Furukawa N; Araki E
    J Diabetes Investig; 2023 Feb; 14(2):189-192. PubMed ID: 36373430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular effects of incretins in diabetes.
    Advani A; Bugyei-Twum A; Connelly KA
    Can J Diabetes; 2013 Oct; 37(5):309-14. PubMed ID: 24500557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence.
    Kawanami D; Matoba K; Sango K; Utsunomiya K
    Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27483245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
    Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
    Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
    Cornell S
    J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incretin drugs as modulators of atherosclerosis.
    Gallego-Colon E; Wojakowski W; Francuz T
    Atherosclerosis; 2018 Nov; 278():29-38. PubMed ID: 30248550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of incretin-based medications: what do current international recommendations suggest with respect to GLP-1 receptor agonists and DPP-4 inhibitors?
    Davies MJ; Bianchi C; Del Prato S
    Metabolism; 2020 Jun; 107():154242. PubMed ID: 32315698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in incretin-based therapies.
    Russell-Jones D; Gough S
    Clin Endocrinol (Oxf); 2012 Oct; 77(4):489-99. PubMed ID: 22804841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013.
    Grunberger G
    J Diabetes; 2013 Sep; 5(3):241-53. PubMed ID: 23489968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond glycemic control: cardiovascular effects of incretin-based therapies.
    Angeli FS; Shannon RP
    Front Horm Res; 2014; 43():144-57. PubMed ID: 24943305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.